Dynavax Technologies Corp (DVAX) Drops 6.52% on January 27

Equities Staff |

Dynavax Technologies Corp (DVAX) was one of the Russell 2000's biggest losers for Wednesday January 27 as the stock slid 6.52% to $24.36, a loss of $-1.7 per share. Starting at an opening price of $25.81 a share, the stock traded between $24.02 and $26.38 over the course of the trading day. Volume was 676,718 shares over 5,804 trades, against an average daily volume of 839,108 shares and a total float of 38.43 million.

The losses send Dynavax Technologies Corp down to a market cap of $936.04 million. In the last year, Dynavax Technologies Corp has traded between $32.49 and $15.80, and its 50-day SMA is currently $25.29 and 200-day SMA is $25.07.

Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The Company is engaged in the development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer.

Dynavax Technologies Corp is based out of Berkeley, CA and has some 197 employees. Its CEO is Eddie Gray.

For a complete fundamental analysis analysis of Dynavax Technologies Corp, check out Equities.com’s Stock Valuation Analysis report for DVAX. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Veritas Pharma Inc.

Veritas Pharma Inc, formerly Seashore Organic Medicine Inc is an emerging producer and distributor of medical marijuana.

Private Markets


Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…